Company Profile

Tapestry Pharmaceuticals Inc (AKA:NaPro BioTherapeutics Inc)
Profile last edited on: 5/13/19

Therapeutics from natural products
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4840 Pearl East Circle Suite 300w
Boulder, CO 80301
   (303) 516-8500
Location: Multiple
Congr. District: 02
County: Boulder

Public Profile

Previously dba NaPro BioTherapeutics, Inc.Tapestry Pharmaceuticals, Inc. had been organized primarily around three elements: production and sale of Paclitaxel, an approved cancer drug; the development of targeted oncology products, and the development of novel genomic technologies, primarily in the area of gene editing for applications in human therapeutics, diagnostics, agribiotechnology and pharmacogenomics. Developing proprietary therapies for the treatment of cancer, the firm also was structured to evaluate new therapeutic agents and related technologies that involve the examination of individual molecules, classes of compounds, and platform technologies. The Company's commercialized product had been Paclitaxel, a naturally occurring chemotherapeutic anti-cancer agent found in certain species of yew, or Taxus, trees. The Company also worked on several types of compounds that have promising activity as anti-cancer agents. NaPro BioTherapeutics had been engaged in evaluating the in-licensing or purchase of potential new products and/or technologies, whether or not those products or technologies are derived from natural products. In December 2003, the Company sold its worldwide generic injectable Paclitaxel business to Mayne Pharma. Duirng the financial crises of 2008 the firm was delisted fromNASDAQ and filed for bankrupcy

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $100,000
Project Title: Selectable Editing of Gene Defects Affecting Solid Tissue

Key People / Management

  Leonard P Shaykin -- CEO

  Leonard P Shaykin -- President

  Martin Batt Sr -- VP, COO

  David L David L -- VP Cancer Biology

  Bruce W Fiedler -- VP, Corporate Controller

  Lawrence Helson -- VP, Bio Research

  Kai P Larson -- VP, General Counsel

  Gordon Link Jr -- VP, CFO

  James D McChesney -- CSO, Natural Products Chemistry

  Patricia A Pilia -- Executive Vice President

  Frank Tagliaferri